scPharmaceuticals Q3 2020 Earnings Report
Key Takeaways
scPharmaceuticals reported a net loss of $9.0 million for the third quarter of 2020. The company is actively engaged with the FDA in their ongoing review of the FUROSCIX NDA and enrolled the first patient in the FREEDOM-HF study.
Continued FUROSCIX commercialization preparedness activities in advance of the company’s December 30, 2020 PDUFA target action date.
Submitted 12-month drug stability data to the U.S. Food and Drug Administration (FDA).
Enrolled the first patient in FREEDOM-HF, a prospective Phase 3 clinical trial evaluating costs for subjects treated with FUROSCIX.
Ended the third quarter with cash, cash equivalents, restricted cash and investments of $114.5 million.
scPharmaceuticals
scPharmaceuticals
Forward Guidance
The Company expects the net loss for 2020 to be lower than prior guidance and in the range of $34.0 to $37.0 million for the fiscal year.